Italia markets closed

SANA Jul 2024 22.500 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,2000+0,1500 (+300,00%)
In data: 12:30PM EDT. Mercato aperto.
Schermo intero
Chiusura precedente0,0500
Aperto0,2000
Denaro0,2000
Lettera0,4500
Prezzo d'esercizio22,50
Scadenza2024-07-19
Min-Max giorno0,2000 - 0,2000
Contratto - Min-MaxN/D
Volume85
Open Interest1
  • GlobeNewswire

    Sana Biotechnology Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data from Four Programs in 2023 and 2024 with a 2024 Operating Burn under $200M

    Increasing focus on ex vivo cell therapy platform based on extensive preclinical and early translational clinical data suggesting ability of hypoimmune (HIP)-modified cells to evade immune detection Human proof of concept data in multiple clinical settings – including oncology, autoimmune diseases, and type 1 diabetes – expected in 2023 and 2024 IND submitted to investigate SC291 in multiple B-cell-mediated autoimmune diseases with initial proof of concept data expected in 2024 Enrollment contin

  • GlobeNewswire

    Sana Biotechnology to Present at September 2023 Investor Conferences

    SEATTLE, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at five investor conferences in September. The presentations will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer, and Nate Hardy, Sana’s Chief Financial Officer. Steve Harr will present at Citi’s 18th Annual BioPharma Conferenc

  • GlobeNewswire

    Sana Biotechnology Reports Second Quarter 2023 Financial Results and Business Updates

    Enrolling patients in ARDENT, the SC291 Phase 1 clinical trial in B-cell malignancies, with initial data expected this year Expect data later this year from investigator-sponsored trial with hypoimmune-modified primary human islet cells Goal to submit INDs this year for both SC262 and SG299 in hematologic cancers Hosted R&D Day, showcasing broad portfolio across platforms, programs, and diseases Announced plan to develop SC291 in autoimmune disorders Shared preclinical data that transplanted all